노인 우울증 환자에서 Aripiprazole과 Bupropion 부가요법의 효과 및 안전성 비교 : 사후분석연구
Augmentation of Aripiprazole versus Bupropion on Specific Symptoms of Depression in Older Adult Patients : A Post-Hoc, Multi-Center, Open-Label, Randomized Study
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives：The purpose of this study was to compare aripiprazole versus bupropion augmentation therapy in older adult patients with major depressive disorder unresponsive to selective serotonin reuptake inhibitors(SSRIs). Methods：This is a post-hoc analysis of a 6-week, randomized prospective open-label multi-center study in thirty older adult patients with major depressive disorder. Participants were randomized to receive aripiprazole(N=16, 2.510mg/day) or bupropion(N=14, 150-300mg/day) for 6 weeks. Montgomery Asberg Depression Rating Scale (MADRS), 17-item Hamilton Depression Rating scale(HAM-D17), Iowa Fatigue Scale, Drug-Induced Extrapyramidal Symptoms Scale, Psychotropic-Related Sexual Dysfunction Questionnaire scores, and Clinical Global Impression-Severity (CGI-S) were obtained at baseline and after one, two, four, and six weeks. Changes on individual items of HAM-D17 were assessed as well as on composite scales(anxiety, insomnia and drive), and on four core subscales that capture core depression symptoms. Results：There was a significantly greater decrease in MADRS scores in aripiprazole group compared to bupropion group at 4(p<0.05) and 6(p<0.05) weeks. There were significantly higher response rate at week 4(p<0.05) and 6(p<0.05) and remission rate at week 6 in aripiprazole group compared to bupropion group. Individual HAM-D17 items showing significantly greater change with adjunctive aripiprazole than bupropion: insomnia, late(ES=0.81 vs. -0.24, p=0.043), psychomotor retardation(ES=1.30 vs. 0.66, p=0.024), general somatic symptoms(ES=1.24 vs. 0.00, p=0.01). On three composite scales, adjunctive aripiprazole was significantly more effective than bupropion with respect to mean change for drive(p=0.005). Conclusion：Results of this study suggested that aripiprazole augmentation have superior efficacy in treating general and core symptoms of depression in older adult patients. Aripiprazole augmentation is associated with greater improvement in specific symptoms of depression such as psychomotor retardation, general somatic symptoms and drive.
Abstract
Objectives：The purpose of this study was to compare aripiprazole versus bupropion augmentation therapy in older adult patients with major depressive disorder unresponsive to selective serotonin reuptake inhibitors(SSRIs). Methods：This is a post-hoc analysis of a 6-week, randomized prospective open-label multi-center study in thirty older adult patients with major depressive disorder. Participants were randomized to receive aripiprazole(N=16, 2.510mg/day) or bupropion(N=14, 150-300mg/day) for 6 weeks. Montgomery Asberg Depression Rating Scale (MADRS), 17-item Hamilton Depression Rating scale(HAM-D17), Iowa Fatigue Scale, Drug-Induced Extrapyramidal Symptoms Scale, Psychotropic-Related Sexual Dysfunction Questionnaire scores, and Clinical Global Impression-Severity (CGI-S) were obtained at baseline and after one, two, four, and six weeks. Changes on individual items of HAM-D17 were assessed as well as on composite scales(anxiety, insomnia and drive), and on four core subscales that capture core depression symptoms. Results：There was a significantly greater decrease in MADRS scores in aripiprazole group compared to bupropion group at 4(p<0.05) and 6(p<0.05) weeks. There were significantly higher response rate at week 4(p<0.05) and 6(p<0.05) and remission rate at week 6 in aripiprazole group compared to bupropion group. Individual HAM-D17 items showing significantly greater change with adjunctive aripiprazole than bupropion: insomnia, late(ES=0.81 vs. -0.24, p=0.043), psychomotor retardation(ES=1.30 vs. 0.66, p=0.024), general somatic symptoms(ES=1.24 vs. 0.00, p=0.01). On three composite scales, adjunctive aripiprazole was significantly more effective than bupropion with respect to mean change for drive(p=0.005). Conclusion：Results of this study suggested that aripiprazole augmentation have superior efficacy in treating general and core symptoms of depression in older adult patients. Aripiprazole augmentation is associated with greater improvement in specific symptoms of depression such as psychomotor retardation, general somatic symptoms and drive.
참고문헌 (32)
- Andrade L, "The epidemiology of major depressive episodes : results from the International Consortium of Psychiatric Epidemiology(ICPE)Surveys", Int J Methods Psychiatr Res, 12, pp.3~21 (2003)
- Lepine JP, "The increasing burden of depression", Neuropsychiatr Dis Treat, 7, pp.3~7 (2011)
- Fava M, "Background and rationale for the sequenced treatment alternatives to relieve depression(STAR*D)study", Psychiatr Clin North Am, 26, pp.457~494 (2003)
- Rush AJ, "Sequenced treatment alternatives to relieve depression(STAR*D) : rationale and design", Control Clin Trials, 25, pp.119~142 (2004)
- Trivedi MH, "Medication augmentation after the failure of SSRIs for depression", N Engl J Med, 354, pp.1243~1252 (2006)
- Moran E, "Effects of bupropion augmentation in escitalopram-resistant patients with major depressive disorder: An open-label, naturalistic study", J Clin Psychiatry, 70, pp.1054~1056 (2009)
- Nelson JC, "Atypical antipsychotic augmentation in major depressive disorder : a meta-analysis of placebo-controlled randomized trials", Am J Psychiatry, 166, pp.980~991 (2009)
- Berman RM, "Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants", CNS Spectr, 14, pp.197~206 (2009)
- Park JH, "Prevalence of major depressive disorder and minor depressive disorder in an elderly Korean population : results from the Korean Longitudinal Study on Health and Aging(KLoSHA)", J Affect Disord, 125, pp.234~240 (2010)
- Schatzberg A, "A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression", Am J Geriatr Psychiatry, 14, pp.361~370 (2006)
- Sheffrin M, "Pilot study of augmentation with aripiprazole for incomplete response in late-life depression : getting to remission", J Clin Psychiatry, 70, pp.208~213 (2009)
- Dew MA, "Recovery from major depression in older adults receiving augmentation of antidepressant pharmacotherapy", Am J Psychiatry, 164, pp.892~899 (2007)
- Fava M, "Diagnosis and definition of treatment-resistant depression", Biol Psychiatry, 53, pp.649~659 (2003)
- 이중서, "한국판 Hamilton 우울증 평가 척도의 신뢰도, 타당도 연구", 신경정신의학, 44(4), pp.456~465 (2005), 대한신경정신의학회
- Cohen J., "Statistical power analysis for the behavior sciences" (1988), Lawrence Earlbaum Associates
- Bech P, "Quantitative rating of depressive states", Acta Psychiatr Scand, 51, pp.161~170 (1975)
- Maier W, "Improving the assessment of severity of depressive states : a reduction of the Hamilton Depression Scale", Pharmacopsychiatry, 18, pp.114~115 (1985)
- Gibbons RD, "Exactly what does the Hamilton depression rating scale measure?", J Psychiatric Res, 27, pp.259~273 (1993)
- Evans KR, "An Item Response analysis of the Hamilton Depression Rating Scale using shared data from two pharmaceutical companies", J Psychiatr Res, 38, pp.275~284 (2004)
- Nelson JC, "Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies", J Affect Disord, 120, pp.133~140 (2010)
- Cheon EJ, "Comparison of the Efficacy and Safety of Aripiprazole Versus Bupropion Augmentation in Patients With Major Depressive Disorder Unresponsive to Selective Serotonin Reuptake Inhibitors: A Randomized, Prospective, Open-Label Study", J Clin Psychopharmacol, 37, pp.193~199 (2017)
- Berman RM, "The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blinde, placebo-controlled study", J Clin Psychiatry, 68, pp.843~853 (2007)
- Berman RM, "Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder", Neuropsychiatr Dis Treat, 7, pp.303~312 (2011)
- Branconnier RJ, "Clinical pharmacology of bupropion and imipramine in elderly depressives", J Clin Psychiatry, 44, pp.130~133 (1983)
- Lenze EJ, "Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial", Lancet, 386, pp.2404~2412 (2015)
- 이가원, "세로토닌 재흡수 억제제에 대한 아리피프라졸 및 부프로피온 부가요법의 우울증 세부증상에 대한 효과 비교 : 다기관, 개방표지, 무작위 연구", 대한불안의학회지, 13(2), pp.66~73 (2017), 대한불안의학회[DOI]
- 금무성, "여성 우울증 환자에서 Aripiprazole과 Bupropion 부가요법의 우울증상 및안전성에 대한 효과 비교 : 사후분석연구", Mood and Emotion, 16(3), pp.140~151 (2018), 대한우울조울병학회
- Lin CH, "Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study", J Clin Psychopharmacol, 31, pp.563~568 (2011)
- Leggio GM, "Dopamine D(3)receptor as a new pharmacological target for the treatment of depression", Eur J Pharmacol, 719, pp.25~33 (2013)
- Marcus RN, "The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder:a second multicenter, randomized, double-blind, placebo-controlled study", J Clin Psychopharmacol, 28, pp.156~165 (2008)
- Clayton AH, "The pathophysiology of hypoactive sexual desire disorder in women", Int J Gynaecol Obstet, 110, pp.7~11 (2010)
- Fava M, "Effects of adjunctive aripiprazole on sexual functioning in patients with major depressive disorder and an inadequate response to standard antidepressant monotherapy: a post hoc analysis of 3 randomized, double-blind, placebo-controlled studies", Prim Care Companion CNS Disord, 13, pp.1~10 (2011)